Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

NCT07087223 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer NSCLC

Interventions

DRUG: Vebreltinib combined with Furmonertinib
DRUG: Vebreltinib combined with Furmonertinib
DRUG: Vebreltinib combined with Furmonertinib

Sponsor

Peking University Cancer Hospital & Institute